The fight against non-alcoholic steatohepatitis (NASH) is a serious form of liver disease called non-alcoholic fatty liver disease (NAFLD), affecting about 20-30% of people worldwide, achieving beneficial effects found A major breakthrough. A compound called 15-Keto-PGE2. NASH causes excessive fat accumulation in the liver, which, if not treated, may lead to serious diseases such as liver scarring and even cancer. The main cause of this disease is obesity, usually due to a high fat diet, which worsens this condition by increasing harmful oxidative stress and resistance to liver insulin.
Professor Lee-Ming Chuang and his team from Taiwan National University have been at the forefront of the study, elucidating the significant findings associated with 15-Keto-PGE2, an agent known for reducing inflammation. “15-Keto-PGE2 brings changes in specific components of NF-KB, a group of proteins that play a key role in controlling inflammation, specifically targeting components P105/p50 and p65. This leads to NF-KB being The ability to drive the inflammatory process in immune cells called macrophages is reduced,” explains Professor Chuang. This finding shows that 15-keto PGE2 can effectively reduce liver inflammation.
In studies of mouse models, the results of treatment with 15-keto PGE2 are important. “In mice with NASH, caused by a long-term diet of fat and sugar, treatment with 15-keto-PGE2 significantly reduced liver inflammation and lowered levels of ALT and AST, indicating liver damage. It also reduced giant The presence of phages, macrophages are immune cells associated with inflammation. “Professor Chuang emphasized. This suggests that 15-one-PGE2 has potential in stopping the development of liver inflammation.
Professor Chuang studied more in-depth “treatment with 15-keto PGE2 in mice with a high-fat and high-sugar diet consistently reduced fasting blood sugar levels and inflammatory substance levels. Similarly, in feeding this diet In the 10-month-month mice, this led to the development of liver disease, which was a six-week treatment with 15-keto-PGE2 reducing liver damage. “These improvements at ALT and AST levels, decreased macrophage activation, and The size of fat deposits in the liver is seen in the reduction.
This study highlights the key role of a group of proteins NF-KB in controlling hepatitis and its activation in the progression of liver diseases such as NAFLD. By specific tests, the study confirmed that 15-Keto-PGE2 attaches to NF-KB components in macrophages and liver tissues. “By affecting the associated homologous domain (RHD) of a portion of p65, 15-Keto-PGE2 is able to prevent p65 from entering the nucleus, thereby reducing activation of the NF-KB pathway, which is known to cause inflammation,” he said. Professor Zhong further explained.
In short, the study of 15-Keto-PGE2 has opened new doors for treatment of Nash, and there are more and more Nash. It has a well-recognized effectiveness in reducing liver inflammation and improving overall liver health, which is 15-keto-PGE2, a potential new therapeutic option for millions of people affected by the disease worldwide.
Journal Reference
Siow-wey Hee, Yi-Cheng Chang, Lynn Su, Daniel Liao, Shiau-Mei Chen, Lee-Ming Chuang, etc. “15-Keto-PGE2 relieves non-alcoholic steatohepatitis by its covalent modification of NF-κB factor.” Iscience (2023). doi:
